"ThinkGenetic is a welcome addition to our global network. Integrating Face2Gene into ThinkGenetic's patient-focused services provides a comprehensive resource for genetic syndromes." Dekel Gelbman, CEO, FDNA
BOSTON (PRWEB) December 14, 2017
ThinkGenetic (http://www.thinkgenetic.com) announced today a collaboration with Boston-based FDNA (http://www.fdna.com) to help patients with undiagnosed genetic diseases. The collaboration enables ThinkGenetic to use FDNA’s Face2Gene suite of next-generation phenotyping applications and user network. Use of Face2Gene will complement the ThinkGenetic SymptomMatcherTM web application, which empowers undiagnosed patients by offering a guided self-assessment of symptoms that may match an underlying genetic disease. SymptomMatcher users can do this from the comfort of their homes and discuss the results with their doctors.
There are more than 350 million people globally with chronic symptoms caused by a rare disease, 80% of which are estimated to be genetic. Most remain undiagnosed, with an average of seven years and seven doctors before receiving a correct diagnosis and an answer. ThinkGenetic is shortening this diagnostic odyssey with SymptomMatcher, a resource to help people find possible explanations for symptoms that they or their loved ones are experiencing.
“Our use of Face2Gene will allow our team to access much-needed insights through a secure web solution,” said Dave Jacob, CEO, ThinkGenetic. “We are proud to lead the way with FDNA using advanced technologies to capture clinically valuable patient information, while partnering with healthcare professionals to facilitate medical evaluation and intervention.”
ThinkGenetic SymptomMatcher allows patients to explore possible causes of their undiagnosed symptoms with the help of proprietary analysis engines and a wealth of detailed information about numerous genetic conditions. They are then offered actionable steps to discuss the results with their doctors for complete evaluation. For patients with immediate general questions before they speak to their doctors, they can contact ThinkGenetic’s team of genetic counselors directly from the application. The team can now review details including Face2Gene’s advanced clinical and genomic insights, as well as help securely refer the patient and the insights to a doctor for evaluation using the Face2Gene application.
Face2Gene is a next-generation phenotyping application that uses facial analysis, artificial intelligence and deep learning to help clinicians discover possible syndromes, genetics or clinical features that may be impacting a patient’s health. With a majority of clinical geneticists globally using Face2Gene, this initiative will help shorten the diagnostic odyssey patients face.
"ThinkGenetic is a welcome addition to our global network," said Dekel Gelbman, CEO, FDNA. "Integrating Face2Gene into ThinkGenetic's patient-focused services provides a comprehensive resource for genetic syndromes. This integration can only bring us closer to an ultimate goal of enabling precision medicine with artificial intelligence to help reduce the time to diagnosis for patients."
About ThinkGenetic - ThinkGenetic locates individuals with diagnosed and undiagnosed genetic diseases using artificial intelligence (AI) solutions. Co-founded by a patient advocate and a genetic counselor, we know firsthand that people can wait a long time to receive a genetic diagnosis. People also have the power within themselves to shorten this diagnostic odyssey. ThinkGenetic helps individuals harness this power by offering trustworthy information to guide them to the help they need, faster. Undiagnosed individuals, patients, and families are our focus and this sets us apart. For more information, visit http://www.ThinkGenetic.com.
About FDNA and Face2Gene - FDNA uses AI to detect physiological patterns that reveal genes affecting your health. Face2Gene is a suite of next-generation phenotyping applications that facilitates comprehensive and precise genetic evaluations. Face2Gene uses facial analysis, deep learning and artificial intelligence to transform big data into actionable genomic insights to improve and accelerate diagnostics and therapeutics. With the world’s largest network of clinicians, labs and researchers creating one of the fastest growing and most comprehensive genomic databases FDNA is changing the game for precision medicine. For more information, visit http://www.FDNA.com. Face2Gene is a registered trademark of FDNA INC.